CF BoNT/A

PreclinicalBiologic

MMerz Therapeutics GmbH

CF BoNT/A is one of 7 biologic programs targeting Cervical Dystonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

Cervical DystoniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Cervical Dystonia

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Phase 2

1 2

IPN10200

Ipsen

Phase 2

1 3

Corabotase

Ipsen

Phase 2

1 4

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 5

Zinc Citrate

UUniversity of Florida

Phase 2

1 6

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

1 7

CF BoNT/A

MMerz Therapeutics GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Dystonia1 trial

Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

Completed·MMerz Therapeutics GmbH··NCT05884528·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CF BoNT/A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CF BoNT/A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CF BoNT/A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merz Therapeutics GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMerz Therapeutics GmbH

CF BoNT/A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Dystonia1 trial

References

Drug Info

Quick Facts

Related News